Alzheimer disease in African American individuals: increased incidence or not enough data?

Alzheimer disease in African American individuals: increased incidence or not enough data?
复制标题

非裔美国人个体中的阿尔茨海默氏病:发病率增加还是没有足够的数据?

DOI:
10.1038/s41582-021-00589-3
复制
发表时间:
2022-01
期刊:
Nature reviews. Neurology
影响因子:
--
通讯作者:
Barnes LL
Barnes LL
中科院分区:
其他
文献类型:
--
作者:
Barnes LL

文献摘要

参考文献

被引文献

相似文献

近年来,对阿尔茨海默病(AD)痴呆症的种族差异研究有所增加。与非拉丁裔白人相比,老年非洲裔美国人承受着不成比例的AD和认知障碍负担。在过去的二十年里,我们对阿尔茨海默病的神经生物学基础的理解取得了巨大的进展。然而,由于研究参与者招募方面的挑战和非洲裔美国人人口生物学数据的持续缺乏,对这些种族差异驱动因素的认识滞后。人们越来越多地寻求治疗靶点和有效的干预措施,但没有更好地了解非裔美国人的疾病,任何确定的治疗和/或治愈都将逃避这一快速增长的高危人群。在这方面,我介绍了在理解阿尔茨海默病的种族差异方面取得进展的三个关键障碍:诊断标准的不确定性,不同的横断面和纵向研究结果;以及缺乏神经病理学数据。我还强调了推动该领域向前发展的循证战略。在这篇文章中,巴恩斯介绍了阻碍我们理解阿尔茨海默病的种族差异的三个主要障碍,并强调了能够推动这一领域向前发展的循证策略。
Research on racial differences in Alzheimer disease (AD) dementia has increased in recent years. Older African American individuals bear a disproportionate burden of AD and cognitive impairment compared with non-Latino white individuals. Tremendous progress has been made over the past two decades in our understanding of the neurobiological substrates of AD. However, owing to well-documented challenges of study participant recruitment and a persistent lack of biological data in the African American population, knowledge of the drivers of these racial disparities has lagged behind. Therapeutic targets and effective interventions for AD are increasingly sought, but without a better understanding of the disease in African American individuals, any identified treatments and/or cures will evade this rapidly growing at-risk population. In this Perspective, I introduce three key obstacles to progress in understanding racial differences in AD: uncertainty about diagnostic criteria, disparate cross-sectional and longitudinal findings; and a dearth of neuropathological data. I also highlight evidence-informed strategies to move the field forward. In this Perspective, Barnes introduces three key obstacles to progress in our understanding of racial differences in Alzheimer disease and highlights evidence-informed strategies that can move the field forward.
DOI: 10.1017/s1355617711001688
发表时间: 2012-03
影响因子: 2.6
作者:
Chin, Alexander L.;Negash, Selam;Xie, Sharon;Arnold, Steven E.;Hamilton, Roy
通讯作者: Hamilton, Roy
DOI: 10.1037/a0031645
发表时间: 2013-09-01
影响因子: 3.7
作者:
Early, Dawnte R.;Widaman, Keith F.;Mungas, Dan
通讯作者: Mungas, Dan
DOI: 10.1093/geronb/51b.6.s319
发表时间: 1996-11-01
影响因子: 6.2
作者:
Ferraro, KF;Farmer, MM
通讯作者: Farmer, MM
DOI: 10.1002/alz.12068
发表时间: 2020-03-01
影响因子: 14
作者:
通讯作者: --
DOI: 10.1001/jamaneurol.2020.0860
发表时间: 2020-08-01
期刊: JAMA NEUROLOGY
影响因子: 29
作者:
Caunca, Michelle R.;Odden, Michelle C.;Al Hazzouri, Adina Zeki
通讯作者: Al Hazzouri, Adina Zeki